Insider · CIK 0001315585
Natasha Giordano
Files at OGEN (ORAGENICS INC), MTNB (Matinas BioPharma Holdings, Inc.). First filing -, latest -.
In brief
Natasha Giordano files SEC Form 4 as director at OGEN (ORAGENICS INC), and also at MTNB (Matinas BioPharma Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Natasha Giordano has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | OGEN ORAGENICS INC | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +38,320 | $0.00 | $0 | 38,320 | Dec 15, 2025 |
| Dec 11, 2025 | OGEN ORAGENICS INC | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Nov 1, 2023 | MTNB Matinas BioPharma Holdings, Inc. | AGrant or award Stock option (right to buy)derivative | +437,244 | $0.00 | $0 | 437,244 | Nov 3, 2023 |
Questions about Natasha Giordano
Answered from the filings on this page, as of the latest one.
Is Natasha Giordano buying or selling?
Natasha Giordano has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Natasha Giordano's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Natasha Giordano has 0.
Where does Natasha Giordano file Form 4?
Natasha Giordano has filed Form 4 at OGEN (ORAGENICS INC); MTNB (Matinas BioPharma Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.